Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance
NCT ID: NCT06351540
Last Updated: 2026-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
40 participants
INTERVENTIONAL
2026-03-01
2026-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-response of Cannabis and Driving
NCT03656029
Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation
NCT01037608
Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes
NCT07214155
A Study Testing the Effects of Different THC Doses on Psychological and Biological Function
NCT07346690
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
NCT02709954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0 mg THC
Inhaled Cannabis - 0 mg THC
Cannabis
cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
5 mg THC
Inhaled cannabis - 5 mg THC
Cannabis
cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
30 mg THC
Inhaled cannabis - 30 mg THC
Cannabis
cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabis
cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* (b) report frequent cannabis use defined as \> 5 days per week for \> 1 year with a positive THC urine toxicology at baseline.
These criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.
Exclusion Criteria
* (2) are currently receiving or interested in immediately receiving behavioral treatment or medication for cannabis cessation,
* (3) current use of any medications that could affect study outcomes,
* (4) test positive for drugs of abuse (other than cannabis) and/or breath alcohol test at study admission,
* (5) have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity,
* (6) are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding,
* (7) have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina), or (8) are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dustin C Lee, PhD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00332797
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.